Three-Pronged attack on blood cancer shows promise
NCT ID NCT05536349
Summary
This study is testing whether a combination of three drugs—pirtobrutinib, venetoclax, and obinutuzumab—is safe and effective for people with two types of blood cancer who have not yet received treatment. It aims to see if this time-limited treatment can deeply reduce or eliminate cancer cells in the body. The trial will enroll 60 adults with either chronic lymphocytic leukemia (CLL) or a more aggressive form called Richter transformation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.